Dr. Marty Makary faces removal as FDA Commissioner under Trump's plan, according to reporting from the New York Times Health section. Makary, a Johns Hopkins surgeon and public health figure, championed the Make America Healthy Again movement but created friction within the administration over several contentious issues.
The conflicts center on three areas. Makary opposed certain vaping products that Trump allies supported. He declined to reverse the FDA's approval of mifepristone, the abortion pill, despite pressure from anti-abortion figures in the administration. He also rejected applications for new drugs that some within the White House wanted greenlighted.
Makary brought significant medical credentials to the role. He previously published research on medical errors and patient safety at Johns Hopkins, and wrote books promoting dietary approaches to health. His appointment aligned with Robert F. Kennedy Jr.'s broader health agenda, which emphasizes skepticism toward pharmaceutical interventions and regulatory reform.
The tension reflects deeper conflicts within Trump's health policy circles. Kennedy and his allies favor faster drug approvals and less regulatory oversight. Makary's decisions, grounded in the FDA's standard evidence-review process, clashed with this direction on multiple occasions.
The vaping disagreement particularly rankled the administration. Trump has maintained complex views on vaping regulation, sometimes supporting restrictions but also prioritizing tobacco industry relationships. Makary's stances created unexpected resistance from within his own camp.
The mifepristone situation proved especially contentious. Despite explicit presidential pressure on abortion access, Makary maintained the FDA's existing approval status for the medication. This decision disappointed figures within the administration who sought rollbacks on reproductive health access.
Drug approvals represented another flashpoint. Makary applied standard FDA protocols for new medications, rejecting those lacking sufficient evidence, while some administration officials wanted faster pathways to market.
These conflicts illustrate the collision between traditional regulatory science and Trump's